

Technical sheet

Idylla™ KRAS Mutation Assay

The Idylla™ KRAS Mutation Assay, performed on the Biocartis Idylla™ system, is a molecular assay for the qualitative detection of 21 mutations in **codons 12, 13, 59, 61, 117 and 146** of the KRAS gene.

The Idylla™ KRAS Mutation Assay, from **sample-to-result**, starts with formalin-fixed paraffin-embedded (FFPE) tissue to liberate DNA for subsequent real-time PCR amplification and detection.



Features

KRAS mutation detection

Codon 12 (exon 2)	G12C	(c.34G>T)
	G12R	(c.34G>C)
	G12S	(c.34G>A)
	G12A	(c.35G>C)
	G12D	(c.35G>A)
	G12V	(c.35G>T)
Codon 13 (exon 2)	G13D	(c.38G>A)
Codon 59 (exon 3)	A59E	(c.176C>A)
	A59G	(c.176C>G)
	A59T	(c.175G>A)
Codon 61 (exon 3)	Q61K	(c.181C>A; c.180_181delinsAA)
	Q61L	(c.182A>T)
	Q61R	(c.182A>G)
	Q61H	(c.183A>C; c.183A>T)
Codon 117 (exon 4)	K117N	(c.351A>C; c.351A>T)
Codon 146 (exon 4)	A146P	(c.436G>C)
	A146T	(c.436G>A)
	A146V	(c.437C>T)

KRAS Total (acting as Sample Processing Control)

Specimen requirements

Sample Type	FFPE tissue sections (5 to 10µm)
Neoplastic cells	≥10%, if less macrodissection is required
Tissue area	50-600mm ² (5µm) 25-300mm ² (10µm)

Total turnaround time

Time	120 minutes
------	-------------

Result Reporting

Report	Qualitative genotype call
--------	---------------------------

Disclaimer

Biocartis trademark and logo are trademarks belonging to Biocartis and are used and registered in Europe. Idylla is a registered trademark in the United States (US) and other countries. Idylla trademark and logo are used trademarks belonging to Biocartis. Idylla™ platform is a CE-marked IVD in Europe. Idylla™ KRAS Mutation Assay is available for Research Use Only (RUO), not for use in diagnostic procedures.